Nestin+ kidney resident mesenchymal stem cells for the treatment of acute kidney ischemia injury

Jiang, Manli; Li, Guilan; Liu, Junfeng; Liu, Longshan; Wu, Bingyuan; Huang, Weijun; Wen, He; Deng, Chao; Wang, Dong; Li, Chunling; Lahn, Bruce T.; Chen, Shi; Xiang, Andy Peng

doi:10.1016/j.biomaterials.2015.01.029

Cited by 62 publications

(53 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, there is a growing consensus that kidney-protective effects of MSCs can be attributed mainly to paracrine and endocrine mechanisms ( Table 1). In support of this hypothesis are recent data obtained using intravenous injection of nestin+ renal-resident MSCs in acute kidney I/R injury; this treatment induced functional improvement by significantly decreasing the serum creatinine and BUN, and reducing the cell apoptosis, but conditioned medium from nestin+ cells could equally protect against ischemic renal failure at least partially through the paracrine factor VEGF [68].…”

Section: Introductionmentioning

confidence: 53%

“…The benefit of cell therapy has been documented in many animal studies [90][91][92], and MSCs have emerged as a promising cell type, due to the allogeneic potential of transplantation, the ability to undergo in vivo renal differentiation (albeit at low levels) and the paracrine mechanisms of action [57][58][59][60][61][62][63][64][65][66][67][68][69][70][77][78][79][80][81][82][83][84][85][86][87]. Potentiating MSCs migration, engraftment, survival and paracrine effects using preconditioning or genetic modification strategies could optimize the beneficial effect of this kind of therapy [118].…”

Section: Expert Opinionmentioning

confidence: 99%

“…The possibility of direct engraftment of MSCs into the kidney is also supported by the demonstration that MSCs directly injected into developing kidney followed by subsequent embryo and organ culture incorporated into glomerulus, tubule and interstitium [63]. However, several other studies showed protection from injury by MSCs, but very little or no tubular incorporation was observed [64][65][66][67][68]. Even if these differences may be explained by different injury models and protocols, or by the method used for tracking injected MSCs, several data argue against the hypothesis that the beneficial effect of MSCs on renal repair is mediated by their engraftment and direct repopulation of the tubule.…”

Section: Introductionmentioning

confidence: 96%

See 2 more Smart Citations

Stem cell therapy for kidney disease

Lazzeri

Romagnani

Lasagni

2015

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Stem cell therapy is a promising new treatment for kidney disease documented in many animal studies. Mesenchymal stem cells have emerged as a promising cell type, but their efficacy in clinical trials is still controversial. Identification of progenitor cells in the adult kidney is another step forward in regenerative medicine, suggesting the repair potential of the adult kidney and the possible modulation of renal progenitors in situ using pharmacological approaches.

show abstract

Section: Introductionmentioning

confidence: 53%

Section: Expert Opinionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Stem cell therapy for kidney disease

Lazzeri

Romagnani

Lasagni

2015

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

“…13,14) Except for neural stem cells, Nestin also have been reported to be expressed in many other tissues, such as the bone marrow, kidney, testis, and hair follicle of the skin, which participate in cell renewal, proliferation, differentiation, and tissue regeneration as well as repair. [15][16][17][18][19] Importantly, previous studies have reported that Nestin was up-regulated in the infarcted myocardium within 48 hours, and further indicated that Nestin + cells participate in the wound healing NESTIN + CELLS ENHANCE SURVIVAL OF DOXORUBICIN INDUCED HL-1 CELLS after myocardial injury. 20,21) However, whether Nestin + cells participated in the pathogenesis of the DCM has not been reported yet.…”

mentioning

confidence: 88%

Cardiac Nestin<sup>+</sup> Cells Derived from Early Stage of Dilated Cardiomyopathy Enhanced the Survival of the Doxorubicin-Injured Cardiac Muscle HL-1 Cells

Xie

Liao

et al. 2018

Int. Heart J.

Self Cite

View full text Add to dashboard Cite

SummaryDilated cardiomyopathy (DCM), as one of the common cardiomyopathies, is a disease of the heart muscle; however, the etiology and pathogenesis of DCM were still poorly understood. Nestin has been reported a special marker of stem/progenitor cells in various tissues, and the tissue resident Nestin + cells could promote the wound healing and tissue remodeling. However, it remains unclear whether Nestin + cells participate in the protection of cardiomyocytes during the pathogenesis of DCM. Here the model of mice DCM was induced by doxorubicin (DOX) intraperitoneal injection and observed heart failure and ventricular enlargement via echocardiography and histologic analysis, respectively. During DCM pathogenesis, the number of Nestin + cells showed a significant peak on day 6 after DOX treatment, which then gradually decreases to lower than normal levels after day 30 in the total population of the heart. Furthermore, we found that the isolated increased heart-derived Nestin + cells are mesenchymal property and could protect DOX-induced HL-1 cells toxicity in vitro by promoting their proliferation and inhibiting their apoptosis. Collectively, our results showed that Nestin + cells increased during DCM pathogenesis and played an important role in protecting against the DOX-induced HL-1 cells loss via regulating proliferation and apoptosis. Thus, the loss of Nestin + cells might be an etiology to DCM pathogenesis, and these cells could be a promising candidate cell source for study and treatment of DCM patients.(Int Heart J 2018; 59: 180-189)

show abstract

“…One study produced single-cell clones from isolated LRCs, but these cells gave rise to heterogeneous populations with morphology that was very dependent on culture conditions [21]. Nestin has been a common marker for identifying stem cells in the papilla, but one group claims that it can be used to identify mesenchymal stem cells resident in the kidney [32]. Nestin+ cells isolated from whole kidney where characterized to have a mix of renal and mesenchymal markers.…”

Section: Renal Stem Cells In the Papillamentioning

confidence: 99%

Comparing adult renal stem cell identification, characterization and applications

Huling

Yoo

2017

J Biomed Sci

View full text Add to dashboard Cite

Despite growing interest and effort, a consensus has yet to be reached in regards to the identification of adult renal stem cells. Organ complexity and low turnover of renal cells has made stem cell identification difficult and lead to the investigation of multiple possible populations. In this review, we summarize the work that has been done toward finding and characterizing an adult renal stem cell population. In addition to giving a general overview of what has been done, we aim to highlight the variation in methods and outcomes. The methods used to locate potential stem cell populations can vary widely, but even within the relatively standard practice of BrdU labeling of slowly dividing cells, there are significant differences in protocols and results. Additional diversity exists in cell marker profiles and apparent differentiation potential seen in potential stem cell sources. Cataloging the variety of methods and outcomes seen so far may help to streamline future investigation and stear the field toward consensus. But even without firmly defined populations, the application of renal stem cells holds tantalizing potential. Populations of highly proliferative, multipotent cells of renal origin show the ability to engraft in injured kidneys, mitigate functional loss and occasionally show the ability to generate nephrons de novo. The progress toward regenerative medicine applications is also summarized.

show abstract

Nestin+ kidney resident mesenchymal stem cells for the treatment of acute kidney ischemia injury

Cited by 62 publications

References 56 publications

Stem cell therapy for kidney disease

Stem cell therapy for kidney disease

Cardiac Nestin<sup>+</sup> Cells Derived from Early Stage of Dilated Cardiomyopathy Enhanced the Survival of the Doxorubicin-Injured Cardiac Muscle HL-1 Cells

Comparing adult renal stem cell identification, characterization and applications

Contact Info

Product

Resources

About